Lung Cancer
Conditions
Interventions
Observation group.:Chemotherapy combined with traditional Chinese medicine inhalation.
Control Group:Pemetrexed plus cisplatin chemotherapy regimen.
Sponsors
Shenzhen Third People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Age between 18 and 60 years (including 18 and 60 years), with no restrictions on gender; (2) Meets the diagnostic criteria for non-squamous cell lung cancer (NSCLC) without genetic drivers; (3) TNM staging of stage IIb to IIIb; (4) Basic normal functions of the heart, liver, kidneys, and hematopoietic system; (5) Expected survival time of = 6 months; (6) Karnofsky Performance Status (KPS) score > 60; (7) Voluntarily participates in this study and signs informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients with other malignant tumors; (2) Patients with severe diseases of other important organs; (3) Patients with severe infections; (4) Individuals with mental disorders; (5) Patients who are allergic to the study medication; (6) Patients receiving other oral traditional Chinese medicine, external treatments, or traditional Chinese patent medicine; (7) Individuals participating in other clinical trials for medications; (8) Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CT; | — |
Secondary
| Measure | Time frame |
|---|---|
| PD-1;NSE;NK Cell;CA125;CEA;CD4 +;CD3 +;EORCT QLQ-C30; | — |
Countries
China
Contacts
Public ContactLu Hongzhou/Zhang Guoliang
Shenzhen Third People's Hospital
Outcome results
None listed